BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10623697)

  • 1. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival.
    Mackay HJ; Cameron D; Rahilly M; Mackean MJ; Paul J; Kaye SB; Brown R
    J Clin Oncol; 2000 Jan; 18(1):87-93. PubMed ID: 10623697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
    Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
    Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.
    Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L
    Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
    Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor buds show reduced expression of laminin-5 gamma 2 chain in DNA mismatch repair deficient colorectal cancer.
    Shinto E; Baker K; Tsuda H; Mochizuki H; Ueno H; Matsubara O; Foulkes WD; Jass JR
    Dis Colon Rectum; 2006 Aug; 49(8):1193-202. PubMed ID: 16773493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
    Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
    Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Ohrling K; Edler D; Hallström M; Ragnhammar P
    Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.
    Andachi H; Yashima K; Koda M; Kawaguchi K; Kitamura A; Hosoda A; Kishimoto Y; Shiota G; Ito H; Makino M; Kaibara N; Kawasaki H; Murawaki Y
    Br J Cancer; 2002 Aug; 87(4):441-5. PubMed ID: 12177781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
    J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
    Branch P; Masson M; Aquilina G; Bignami M; Karran P
    Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix.
    Giarnieri E; Mancini R; Pisani T; Alderisio M; Vecchione A
    Clin Cancer Res; 2000 Sep; 6(9):3600-6. PubMed ID: 10999751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
    Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
    Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
    Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
    Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.
    Yndestad S; Austreid E; Knappskog S; Chrisanthar R; Lilleng PK; Lønning PE; Eikesdal HP
    Breast Cancer Res Treat; 2017 May; 163(1):177-190. PubMed ID: 28213783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.